Literature DB >> 8142192

Ten year mortality in relation to original size of myocardial infarct: results from the Gothenburg metoprolol study.

J Herlitz1, B W Karlson, A Hjalmarson.   

Abstract

OBJECTIVE: To describe the relation between the extent of a myocardial infarct, measured according to maximum serum enzyme activity of lactate dehydrogenase, and mortality at 10 years. PATIENTS: In 759 patients with acute myocardial infarction in whom serum activity of heat stable lactate dehydrogenase had been determined every 12 hours for 108 hours after randomisation in an early intervention trial with metoprolol. MAIN OUTCOME MEASURE: Mortality at 10 years in relation to quartile of maximum serum lactate dehydrogenase activity and history of cardiovascular disease.
RESULTS: Among all patients mortality at 10 years was 39% in the lowest quartile, 51% in the second quartile, 50% in the third, and 59% in the fourth (p < 0.001 for relation between infarct size and 10 year mortality). Among patients without a history of myocardial infarction, angina pectoris, diabetes mellitus, or hypertension the mortality in each quartile was 29%, 32%, 41%, and 56%, respectively (p < 0.001 for relation between infarct size and 10 year mortality). Among patients with any of these risk indicators the association between the estimated infarct size and mortality at 10 years was weak (p < 0.05).
CONCLUSION: Estimated size of a myocardial infarct and mortality over 10 years seem to be related but mainly in patients without a history of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142192      PMCID: PMC483660          DOI: 10.1136/hrt.71.3.238

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  27 in total

1.  Validity of estimating myocardial infarct size from serial measurements of enzyme activity in the serum.

Authors:  C R Roe
Journal:  Clin Chem       Date:  1977-10       Impact factor: 8.327

2.  Reduction of enzyme levels by propranolol after acute myocardial infarction.

Authors:  T Peter; R M Norris; E D Clarke; M K Heng; B N Singh; B Williams; D R Howell; P K Ambler
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

3.  Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial.

Authors:  A Hjalmarson; D Elmfeldt; J Herlitz; S Holmberg; I Málek; G Nyberg; L Rydén; K Swedberg; A Vedin; F Waagstein; A Waldenström; J Waldenström; H Wedel; L Wilhelmsen; C Wilhelmsson
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

4.  Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death.

Authors:  R M Norris; P F Barnaby; P W Brandt; G G Geary; R M Whitlock; C J Wild; B G Barratt-Boyes
Journal:  Am J Cardiol       Date:  1984-02-01       Impact factor: 2.778

5.  Relationship between the enzymatically estimated infarct size and clinical findings in acute myocardial infarction.

Authors:  J Herlitz; J Waldenström; A Hjalmarson
Journal:  Acta Med Scand       Date:  1984

6.  Patterns of creatine kinase release during acute myocardial infarction after nonsurgical reperfusion: comparison with conventional treatment and correlation with infarct size.

Authors:  H Blanke; D von Hardenberg; M Cohen; H Kaiser; K R Karsch; J Holt; H Smith; P Rentrop
Journal:  J Am Coll Cardiol       Date:  1984-03       Impact factor: 24.094

7.  Predictors of clinical course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction.

Authors:  G J Taylor; J O Humphries; E D Mellits; B Pitt; R A Schulze; L S Griffith; S C Achuff
Journal:  Circulation       Date:  1980-11       Impact factor: 29.690

8.  Correlation between enzymatic estimation of infarct size and early mortality rate.

Authors:  J Herlitz; A Hjalmarson; J Waldenström; K Swedberg; F Waagstein; A Waldenström
Journal:  Br Heart J       Date:  1983-12

9.  Effect of metoprolol on indirect signs of the size and severity of acute myocardial infarction.

Authors:  J Herlitz; D Elmfeldt; A Hjalmarson; S Holmberg; I Málek; G Nyberg; L Rydén; K Swedberg; A Vedin; F Waagstein; A Waldenström; J Waldenström; H Wedel; L Wilhelmsen; C Wilhelmsson
Journal:  Am J Cardiol       Date:  1983-05-01       Impact factor: 2.778

10.  Acute myocardial infarct size estimated by serum CK-MB determinations: clinical accuracy and prognostic relevance utilizing a practical modification of the isoenzyme approach.

Authors:  P Grande; B F Hansen; C Christiansen; J Naestoft
Journal:  Am Heart J       Date:  1981-05       Impact factor: 4.749

View more
  4 in total

1.  Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α.

Authors:  M Ahsan Siraj; Dhanwantee Mundil; Sanja Beca; Abdul Momen; Eric A Shikatani; Talat Afroze; Xuetao Sun; Ying Liu; Siavash Ghaffari; Warren Lee; Michael B Wheeler; Gordon Keller; Peter Backx; Mansoor Husain
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

2.  Pharmacokinetics and safety of a single dose of the novel necrosis inhibitor LC28-0126 in healthy male subjects.

Authors:  Seokuee Kim; Hyewon Chung; SeungHwan Lee; Sang-Heon Cho; Hyun-Jai Cho; Soon Ha Kim; In-Jin Jang; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2017-01-25       Impact factor: 4.335

Review 3.  Use of carvedilol in hypertension: an update.

Authors:  Gastone Leonetti; Colin G Egan
Journal:  Vasc Health Risk Manag       Date:  2012-05-18

4.  Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction.

Authors:  Thomas Bochaton; Nathan Mewton; NDieme Thiam; Fabien Lavocat; Delphine Baetz; Nathalie Dufay; Cyril Prieur; Eric Bonnefoy-Cudraz; Pierre Miossec; Michel Ovize
Journal:  PLoS One       Date:  2017-11-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.